Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Oncology
Non-Small Cell Lung Cancer
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Lung Cancer Study CASA404A2302
Lung Cancer Study CASA404A2302
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Lung Cancer Study CASA404A2302
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
A Phase II Randomized Study of Erlotinib (Tarceva, OSI-774) as a Single Agent or Intercalated with Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer that have EGFR Overexpression and/or EGFR Amplification and/or Mutation
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
ACOSOG Z4032: A Randomzied Phase III Study of Sublobar Resection Versus Sublobar Resection Plus Brachytherapy in High-Risk Patients with Non-Small Cell Lung Cancer (NSCLC), 3cm or Smaller
OSI Radiant: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Single-Agent Tarceva (Erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-Small Cell Lung Carcinoma who have EGFR Positive Tumors
PHII-70 NCI #7077: Randomized Phase II Trial of Sequential versus Concurrent Docetaxel and PS-341 (NSC 681239, IND 58,443) in Previously Treated Non-Small Cell Lung Cancer
PHII-74 NCI #7437 A Phase II study of E7389 Halichondrin B Analog (NSC #707389; IND #64395) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated with a Taxane
SWOG S0424: Molecular Epidemiology Case-Series Study of NSCLC in Smoking and Non-Smoking Women and Men
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) having Received Tarceva Monotherapy.
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Lung Cancer Study CASA404A2302
A Phase II Randomized Study of Erlotinib (Tarceva, OSI-774) as a Single Agent or Intercalated with Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer that have EGFR Overexpression and/or EGFR Amplification and/or Mutation
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Lung Cancer Study CASA404A2302
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Phase II Trial of First-Line Therapy With Gemcitabine, Docetaxel and Cetuximab in Patients With Unresectable Stage III or IV Non-Small Cell Lung Cancer
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) having Received Tarceva Monotherapy.
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Lung Cancer Study CASA404A2302
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Lung Cancer Study CASA404A2302
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC)
ECOG E5597 "Phase III chemoprevention trial of selenium supplementation in persons with resected stage I non-small cell lung cancer
Patients who have undergone complete resection of a histologically proven stage IA(pT1N0) or stage IB(pT2N0)non-small cell lung cancer
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Lung Cancer Study CASA404A2302
Randomized, Multi-Center, Open-Label, Study of Docetaxel Versus Docetaxel/PR104 in Non-Small Cell Lung Cancer (NSCLC)
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Lung Cancer Study CASA404A2302
Lung Cancer Study CASA404A2302
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Cancer: Volunteers Needed for Lung Cancer Vaccine Research Study
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Lung Cancer Study CASA404A2302
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
Lung Cancer Study CASA404A2302
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) having Received Tarceva Monotherapy.
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Lung Cancer Study CASA404A2302
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Phase II Randomized Study of Erlotinib (Tarceva, OSI-774) as a Single Agent or Intercalated with Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer that have EGFR Overexpression and/or EGFR Amplification and/or Mutation
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Lung Cancer Study CASA404A2302
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Study of Sublobar Resection Versus Sublobar Resection Plus Brachytherapy in High-Risk Patients with Non-Small Cell Lung Cancer (NSCLC), 3cm or Smaller
Lung Cancer Study CASA404A2302
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Non-small Cell Lung Cancer (NSCLC)
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other than Predominantly Squamous Cell Histology - Adults
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) having Received Tarceva Monotherapy.
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Non Small Cell Lung Cancer (NSCLC) - Adults and minors
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Lung Cancer Study CASA404A2302
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) having Received Tarceva Monotherapy.
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
Randomized Phase II Study of First-Line Treatment with Gemcitabine vs. Erlotinib vs. Gemcitabine and Erlotinib in Elderly Patients with Stage (IIIB/IV) Non-Small Cell Lung Cancer
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Lung Cancer Study CASA404A2302
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Epothilone D in Patients With Non-Small Cell Lung Cancer (NSCLC)
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Lung Cancer Study CASA404A2302
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Phase II Randomized Study of Erlotinib (Tarceva, OSI-774) as a Single Agent or Intercalated with Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer that have EGFR Overexpression and/or EGFR Amplification and/or Mutation
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
An Open Label, Randomized Phase I/IIa Trial Evaluating MK0646 in Combination With Erlotinib for Patients With Recurrent Non-Small Cell Lung Cancer
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Lung Cancer Study CASA404A2302
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
An Open Label, Randomized Phase I/IIa Trial Evaluating MK0646 in Combination With Erlotinib for Patients With Recurrent Non-Small Cell Lung Cancer
Lung Cancer Study CASA404A2302
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Lung Cancer Study CASA404A2302
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
Lung Cancer Study CASA404A2302
This is a study to evaluate the effectiveness of Tarceva ® (erlotinib) tablets vs. placebo (sugar pill) following complete surgical removal of the tumor with or without chemotherapy after surgery in IB-IIIA NSCLC patients.
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Lung Cancer Study CASA404A2302
Lung Cancer Study CASA404A2302
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Pilot Study of FDG- and FLT PET in Patients With Non-Small Cell Lung Cancer Treated with Tarceva (Erlotinib).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Pilot Study of FDG- and FLT PET in Patients With Non-Small Cell Lung Cancer Treated with Tarceva (Erlotinib).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
A Pilot Study of FDG- and FLT PET in Patients With Non-Small Cell Lung Cancer Treated with Tarceva (Erlotinib).
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Pilot Study of FDG- and FLT PET in Patients With Non-Small Cell Lung Cancer Treated with Tarceva (Erlotinib).
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
A Study of Pertuzumab in Combination With Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MERIT Study - A Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer.
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) having Received Tarceva Monotherapy.
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) having Received Tarceva Monotherapy.
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer.
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) having Received Tarceva Monotherapy.
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.
A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.
A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MERIT Study - A Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.
A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MERIT Study - A Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.
A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy.
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) having Received Tarceva Monotherapy.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MERIT Study - A Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) having Received Tarceva Monotherapy.
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MERIT Study - A Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer (NSCLC)
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy.
A Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Chemotherapy
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) having Received Tarceva Monotherapy.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy.
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
MERIT Study - A Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer (NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
Stimuvax® START (Stimulating Targeted Antigenic Response to NSCLC)
MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).
MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
